Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · technology

Sefaxersen Meets Primary Endpoint in Phase 3 IgA Nephropathy Trial

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

technology

◆ Sectors

BiotechDrug Discovery

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Sefaxersen met the primary endpoint in the Phase 3 IMAgINATION clinical trial for IgA nephropathy, marking a significant milestone for Roche and Ionis in this kidney disease treatment development.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 3 sources have reported it between 23 Sep 2026 and 25 Sep 2026.

◆ ◆ The Wire takeaway

You now have clearer validation of sefaxersen's potential as a treatment for IgA nephropathy, so expect trial-readiness investors and partners to sharpen focus on kidney disease innovations this quarter.

◆ Coverage

3 sources · first reported 23 Sep 2026 · latest 25 Sep 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryphase-3clinical-trialiga-nephropathysefaxersenrocheionis